The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

Yekeduz, Emre; Tural, Deniz; Erturk, Ismail; Karakaya, Serdar; EROL, CİHAN; Ercelep, Ozlem; Arslan, Cagatay; Sever, Ozlem; KILIÇKAP, SAADETTİN; Senturk Oztas, Nihan; Kucukarda, Ahmet; Can, Orcun; Oksuzoglu, Berna; ŞENDUR, MEHMET; Karadurmus, Nuri; ÜRÜN, YÜKSEL

doi:10.1007/s00432-022-04055-5

The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

Copy For Citation

Yekeduz E., Tural D., Erturk I., Karakaya S., EROL C., Ercelep O., ...More

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.148, no.12, pp.3537-3546, 2022 (SCI-Expanded)

Publication Type: Article / Article
Volume: 148 Issue: 12
Publication Date: 2022
Doi Number: 10.1007/s00432-022-04055-5
Journal Name: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Page Numbers: pp.3537-3546
Keywords: Immunotherapy, Renal cell carcinoma, Biomarker, TO-LYMPHOCYTE RATIO, INDEX SII, PROGNOSTIC-FACTORS, THERAPIES, MRCC
Hacettepe University Affiliated: Yes

Abstract

Background Pan-immune-inflammation value (PIV) is an easily accessible immune marker based on peripheral blood to estimate prognosis in patients with cancer. This study evaluates the prognostic value of PIV in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab.